Company Presentation Dec 09, 2024 Company Presentation Other Presentations December 9, 2024 ASH 2024: First Phase 1 Clinical Results of IMPT-314, an Autologous Dual-Targeting CD19/CD20 CAR T-cell Product Candidate Enriched for Naïve and Central Memory T Cells, for the Treatment of Large B-cell Lymphoma November 9, 2024 SITC 2024: Utilizing Stim-R™ Technology to Reduce IrradiatedFeeder Cell Use in the Tumor Infiltrating Lymphocyte Culture Process November 8, 2024 SITC 2024: Multiomic Profiling of LYL119: Reprogramming ROR1CAR T cells With Reduced Exhaustion and Enhanced Memory Characteristics IsAssociated With Increased AP-1 and ReducedNR4A Binding November 8, 2024 SITC 2024: LYL797 Reprogrammed ROR-1 CAR T cells Demonstrate Limited Exhaustion, Maintenance of Stemness and Tumor Infiltration with Evidence of Tumor Lysis in Patients with Solid Tumors October 24, 2024 Lyell Strengthens Next Generation CAR TCell Pipeline June 26, 2024 Initial Clinical and Translational Data from Phase 1 Trial of LYL797, an Enhanced ROR1-targeted CAR-T Cell Product Candidate April 9, 2024 AACR 2024: Development of Tumor-restricted IL-12 With Antigen-dependent Expression and Localized IL-12 Activity April 7, 2024 AACR 2024: Preclinical ROR1-Targeted CAR T-Cell Product Incorporating Four Novel Reprogramming Technologies Designed for Effective Cell Therapy for Solid Tumors November 4, 2023 SITC 2023: Preclinical development of LYL119, a ROR1-targeted CAR T-cell product incorporating four novel T-cell reprogramming technologies to overcome barriers to effective cell therapy for solid tumors November 4, 2023 SITC 2023: Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell therapy enhanced with genetic and epigenetic reprogramming, in advanced triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
